(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 7 April 2005 (07.04.2005)

PCT

(10) International Publication Number WO 2005/031365 A3

(51) International Patent Classification7: C07K 14/475, G01N 33/543

G01N 33/68.

(21) International Application Number:

PCT/IB2004/003606

(22) International Filing Date:

29 September 2004 (29.09.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/507,192

29 September 2003 (29.09.2003) US

(71) Applicants and

(72) Inventors: NAYERI, Fariba [SE/SE]; Westmansgatan 100A, S-582 16 Linköping (SE). NAYERI, Tayeb [SE/SE]; Bjälbogatan 8C, S-582 47 Linköping (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report: 7 July 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RAPID DETERMINATION OF HEPATOCYTE GROWTH FACTOR (HGF) IN THE BODY FLUIDS

(57) Abstract: A method for diagnosing an inflammatory disorder in an individual comprises contacting a body fluid sample from the individual with an immunoassay device to determine relative levels of different forms of hepatocyte growth factor (HGF) in the sample, and correlating the determined levels to an inflammatory disorder. An immunoassay device for diagnosing an inflammatory disorder in an individual comprises at least two test areas having immobilized respectively therein reagent for binding different forms of hepatocyte growth factor (HGF).